Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625971 · ClinicalTrials.gov registry record
Non-invasive MRD Assessment in Multiple Myeloma
A clinical trial, sponsored by Rajshekhar Chakraborty, MD.
- Completed
- Registry status
- 36
- Enrollment target
NCT05625971 is a clinical trial that has completed, run by Rajshekhar Chakraborty, MD. The registered enrollment target is 36 participants.
The verdict
NCT05625971 has completed, sponsored by Rajshekhar Chakraborty, MD.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investigate whether non-invasive methods for MRD assessment can replace bone marrow aspiration and biopsy in a substantial percentage of participants with multiple myeloma.
Interventions
- OTHER MRD Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2025-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625971
The ClinicalTrials.gov registry entry for NCT05625971 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rajshekhar Chakraborty, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MRD Assessment is the first listed.
NCT05625971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05625971 about?
NCT05625971 is a clinical study titled "Non-invasive MRD Assessment in Multiple Myeloma". The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investig...
What is the current status of trial NCT05625971?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2022-09-14. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT05625971?
The interventions under investigation include: MRD Assessment (OTHER).
Who is sponsoring clinical trial NCT05625971?
This trial is sponsored by Rajshekhar Chakraborty, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.